PSQ Holdings is no longer trying to be a values marketplace with a baby-care brand attached. Under Dusty Wunderlich, who took the chair and the chief executive role after founder Michael Seifert stepped down in late January, the company is stripping itself down to a payments and consumer-credit shop for merchants that mainstream banks treat as reputationally toxic. The June quarter is the first clean test of that subtraction. Continuing-operations revenue more than doubled from the year-ago period, while the payroll was cut roughly in half. The question is not whether the top line can grow from a small base. The question is whether a still-lossy fintech can fund that growth before the listing clock and the convertible stack force another trip to the equity window.
The operating print looks like progress until the balance sheet is put beside it. Non-GAAP operating income flipped to a slim profit after a year-ago loss, and cash used in operations fell by about half versus the prior-year quarter. That improvement sits on a thin cushion. Cash and restricted cash ended June near $8 million, against a revolver already drawn to fund Credova originations and more than $28 million of convertible notes, most of it owed to a related party. Equity at mid-year was only about $4 million. The market is being asked to treat a cost-cut and a pending brand sale as proof that the residual claim is healing, when the residual claim is still a sliver sitting under a heavy paper stack.
The EveryLife sale to FreeHold Brands, signed in late July for about $5 million of gross cash, is the near-term liquidity event, not a change in what the company sells. Payments volume more than doubled year over year, and Credova credit volume grew at a slower but still solid clip, yet both lines slipped sequentially from the first quarter. Management is holding a full-year continuing-operations revenue outlook near $32 million and talking about cash-flow inflection sometime in the following year. Does a seasonal second-half lift, plus one modest asset sale, close the gap between a shrinking cash pile and a New York Stock Exchange market-cap cure that still requires the equity to look several times larger than it does today?